Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) ended Friday session in red amid volatile trading. The shares closed down -0.06 points or -1.09% at $5.42 with 1.11 million shares getting traded. Post opening the session at $5.49, the shares hit an intraday low of $5.38 and an intraday high of $5.58 and the price vacillated in this range throughout the day. The company has a market cap of $567.67 million and the numbers of outstanding shares have been calculated to be 105.90 million shares.
Keryx Biopharmaceuticals (KERX), a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Shares of XOMA Corp (NASDAQ:XOMA) ended Friday session in red amid volatile trading. The shares closed down -0.026 points or -5.78% at $0.424 with 1.17 million shares getting traded. Post opening the session at $0.45, the shares hit an intraday low of $0.42 and an intraday high of $0.47 and the price vacillated in this range throughout the day. The company has a market cap of $51.15 million and the numbers of outstanding shares have been calculated to be 120.59 million shares.
XOMA Corp (XOMA) provided an update on its ongoing XOMA 358 Phase 2 studies in patients with severe hypoglycemia due to congenital hyperinsulinism (CHI) and post-bariatric surgery (PBS), two rare conditions resulting from abnormal insulin function.
“The initial data from the XOMA 358 Phase 2 clinical studies confirms that our first-in-class allosteric antibody is exhibiting an inhibition on insulin signaling, the desired mechanism-of-action. This means that for patients who are not able to properly regulate their high insulin levels and experience severe bouts of hypoglycemia, such as those diagnosed with congenital hyperinsulinism and certain post-bariatric surgery patients, XOMA 358 could provide benefit in preventing hypoglycemic episodes,” stated John Varian, Chief Executive Officer of XOMA. “When we consider the totality of preclinical and clinical evidence, which demonstrates that XOMA 358 down-regulates insulin signaling by binding to the insulin receptor in an allosteric manner, we believe XOMA 358 is ready for advancement into Phase 2b multi-dose studies.